XNCR Xencor Inc

Nasdaq Pharmaceutical Preparations DE CIK: 0001326732
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

Xencor faces acute financial distress with only $14.2M in cash reserves while burning $68.2M annually in free cash flow, representing less than 2.5 months of operational runway. The company's $4.5M in revenue cannot support its $77.9M operating expense base, with net losses of $128.9M indicating fundamental economic dysfunction. Immediate financing need or drastic restructuring is required to ensure survival.

Strengths

  • + Low leverage with debt-to-equity ratio of 0.16x indicates manageable debt burden
  • + Reasonable asset base of $736.8M provides collateral for potential financing
  • + Revenue growth of 13.7% YoY demonstrates some market acceptance and commercial traction

Risks

  • ! Critical liquidity crisis: $14.2M cash with $68.2M annual burn rate equals approximately 2.5 months of runway
  • ! Operating losses of $77.9M vastly exceed revenues of $4.5M, indicating unsustainable business model
  • ! Net losses of $128.9M annually with operating margins of -1724% show no visible path to profitability

Key Metrics to Watch

Financial Metrics

Revenue
4.5M
Net Income
-128.9M
EPS (Diluted)
$-1.71
Free Cash Flow
-68.2M
Total Assets
736.8M
Cash
14.2M

Profitability Ratios

Gross Margin N/A
Operating Margin -1,724.1%
Net Margin -2,854.7%
ROE -25.0%
ROA -17.5%
FCF Margin -1,511.0%

Balance Sheet & Liquidity

Current Ratio
6.57x
Quick Ratio
6.57x
Debt/Equity
0.16x
Debt/Assets
30.0%
Interest Coverage
-4,866.38x
Long-term Debt
82.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-08T13:06:35.591922 | Data as of: 2026-03-31 | Powered by Claude AI